Financial Performance - The company's revenue for 2021 was approximately RMB 1.77 billion, representing a 32.61% increase compared to RMB 1.33 billion in 2020[16]. - The net profit attributable to shareholders for 2021 was approximately RMB 352.24 million, a 53.10% increase from RMB 230.07 million in 2020[16]. - The net cash flow from operating activities for 2021 was approximately RMB 342.29 million, reflecting a 30.61% increase compared to RMB 262.07 million in 2020[16]. - The total assets at the end of 2021 were approximately RMB 6.95 billion, a 10.35% increase from RMB 6.30 billion at the end of 2020[16]. - The company's net assets attributable to shareholders at the end of 2021 were approximately RMB 5.71 billion, a 4.06% increase from RMB 5.49 billion at the end of 2020[16]. - The basic earnings per share for 2021 were RMB 2.00, a 53.85% increase from RMB 1.30 in 2020[17]. - The diluted earnings per share for 2021 were RMB 2.00, consistent with the basic earnings per share[17]. - The net profit after deducting non-recurring gains and losses for 2021 was approximately RMB 327.96 million, a 58.88% increase from RMB 206.43 million in 2020[16]. - The total amount of non-recurring gains and losses was 24,270,714.28 RMB, showing a slight increase from 2020[21]. Dividend and Share Capital - The company plans to distribute a cash dividend of 7.00 CNY per 10 shares, totaling approximately 123.08 million CNY, which accounts for 34.94% of the net profit attributable to shareholders for the year 2021[3]. - The total share capital of the company as of the report date is 175,822,100 shares[3]. - The company does not plan to increase capital reserves or issue bonus shares[3]. Corporate Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors and senior management confirm the authenticity, accuracy, and completeness of the annual report[2]. - There are no significant non-operating fund occupations by controlling shareholders or related parties[4]. - There are no violations of decision-making procedures regarding external guarantees[5]. - The company has not disclosed any special arrangements for corporate governance[5]. - The report includes a forward-looking statement risk declaration, indicating potential risks in future plans and strategies[4]. Research and Development - The R&D expenditure as a percentage of revenue for 2021 was 9.48%, slightly down from 9.49% in 2020[17]. - The company reported a significant increase in R&D expenditure compared to 2020, contributing to future growth despite rising operational costs[18]. - The company has increased its R&D investment to develop new technologies and products, focusing on collaboration with renowned universities and research institutions[67]. - The company has a comprehensive R&D project management system, primarily relying on its internal teams for product development[67]. - The company has developed a range of core technologies, including the BioVue® surface modification technology for artificial lenses and innovative preparation techniques for hyaluronic acid products[70]. - The company has filed for 42 new patents during the reporting period, with a total of 311 patents granted to date[78]. - The company is currently developing 22 projects, with 11 projects in clinical trials and 11 in preclinical research stages[83]. Market Performance and Strategy - The company maintained a 45.24% market share in the ophthalmic viscoelastic device market in China, leading the market for 14 consecutive years[26]. - The company is focusing on expanding its product lines in ophthalmology and medical aesthetics, with new products entering clinical trials and ongoing development of innovative solutions[24]. - The company achieved total revenue of RMB 1,766.99 million in 2021, an increase of RMB 434.57 million, representing a growth rate of 32.61% compared to the previous year[23]. - The company is the largest producer of orthopedic joint cavity viscoelastic supplements in China, with a market share that has grown from 42.06% in 2019 to 43.30% in 2020[44]. - The company is exploring new strategies in market expansion and product development, particularly in the field of ophthalmic and orthopedic treatments[83]. Acquisitions and Investments - The company acquired 55% of Hengtai Vision and secured exclusive distribution rights for high-end corneal reshaping contact lenses in mainland China, enhancing its market presence[33]. - The company acquired 60% of Hebei Xinkang, which has approved medical device registrations for various soft contact lenses, facilitating the production of new myopia control products[36]. - The group acquired a 63.64% stake in Euroha Medical for RMB 205 million, expanding its product offerings in the field of radiofrequency and laser medical beauty devices[41]. - The company plans to invest up to USD 31 million in Eirion for exclusive rights to develop and commercialize innovative botulinum toxin products in Greater China[42]. Financial Position and Cash Flow - The net cash flow from investing activities turned negative at -148.09 million RMB, a significant decrease compared to the previous year's positive cash flow[119]. - The net cash flow from financing activities also increased to -231.25 million RMB, mainly due to the repayment of short-term bank loans[119]. - The company reported a financial net income of 84.85 million RMB, a decrease of 14.40% due to declining deposit interest rates[118]. - The company’s total assets at the end of the reporting period amounted to 6,949,000,000.00 CNY, with a significant increase in inventory by 39.05% to 354,765,098.16 CNY due to proactive procurement strategies[121]. Market Trends and Opportunities - The company anticipates continued growth in the ophthalmology market, driven by increasing health awareness and payment capabilities among consumers[127]. - The market size for orthopedic joint cavity viscoelastic supplements in China was approximately CNY 1.837 billion in 2020, a year-on-year decrease of 14.4%, and is expected to grow to CNY 2.111 billion by 2026, with a CAGR of about 1.9% from 2021 to 2026[132]. - The Chinese medical beauty market size is expected to reach CNY 184.6 billion in 2021, with a year-on-year growth of over 20%[130]. - The number of myopia patients in China has exceeded 600 million, with the youth myopia rate being the highest in the world, indicating a significant market demand for myopia prevention and correction products[129]. Management and Governance - The company has appointed several directors and executives across various subsidiaries, including positions in Haohai Holdings and Haohai Cayman, indicating a strong leadership structure[187]. - The management team includes individuals with extensive experience in the medical technology field, which may contribute to future innovations and product developments[188]. - The company has maintained a consistent presence in the market with key personnel serving in their roles for several years, ensuring stability and continuity in leadership[187]. - The company has established specialized committees, including an audit committee and a strategic committee, to enhance governance[196].

2021 年第三季度报告 单位：元 币种：人民币 证券代码：688366 证券简称：昊海生科 上海昊海生物科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 本报告期 年初至报告期 | --- | --- | --- | --- | --- | |------------------------------------------------|----------------|------------------------------|------------------|------------------------ ...

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2021, representing a year-on-year increase of 15%[2]. - The net profit attributable to shareholders was 300 million RMB, up 20% compared to the same period last year[2]. - The company's operating revenue for the first half of 2021 was approximately ¥851.23 million, representing a 71.63% increase compared to ¥495.96 million in the same period last year[25]. - The net profit attributable to shareholders for the same period was approximately ¥231.02 million, a significant increase of 739.25% from ¥27.53 million year-on-year[26]. - The net profit after deducting non-recurring gains and losses reached approximately ¥220.99 million, up 2,722.36% from ¥7.83 million in the previous year[25]. - The net cash flow from operating activities increased by 197.73%, amounting to approximately ¥120.79 million compared to ¥40.57 million in the same period last year[26]. - Basic earnings per share rose to ¥1.31, reflecting a growth of 773.33% from ¥0.15 in the previous year[29]. - The gross profit margin for the reporting period was 74.53%, down from 77.21% in the same period last year, primarily due to price reductions in certain models of artificial lenses and hyaluronic acid products[92]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 30% increase in market share by the end of 2022[2]. - The company plans to launch three new products in the next quarter, focusing on advanced medical technologies[2]. - Future guidance estimates a revenue growth of 10-15% for the second half of 2021[2]. - The company has implemented a new digital marketing strategy, aiming to improve customer engagement and retention rates by 20%[2]. - The company holds a leading position in the artificial lens market, with an annual sales volume accounting for approximately 30% of the market usage in China[34]. - The company is committed to becoming a leader in the biomedical materials field through technological innovation and resource integration[33]. Research and Development - Research and development expenses increased by 18%, totaling 150 million RMB, to support innovation initiatives[2]. - The company's R&D investment as a percentage of operating revenue was 8.63%, a decrease of 2.78 percentage points from 11.41% in the previous year[25]. - The company has a comprehensive R&D management system, focusing on internal development and collaboration with leading universities and hospitals to enhance technology and product innovation[54]. - Key technologies include advanced manufacturing processes for hydrogels and intraocular lenses, with several patents filed to protect innovations[55]. - The company continues to invest in R&D to develop new technologies and products, ensuring a competitive edge in the pharmaceutical and medical device sectors[54]. - The company’s R&D expenses for the reporting period amounted to CNY 73.49 million, an increase of 29.90% compared to the previous year, representing 8.63% of total revenue[63][67]. Product Development and Clinical Trials - The company has initiated clinical trials for its fourth-generation organic cross-linked hyaluronic acid product, expanding its product portfolio in the high-end market[37]. - The company is advancing the clinical trials of a new orthokeratology lens product based on its proprietary optical design system[35]. - The company has developed a new pig-derived fibrin adhesive, approved for registration by the National Medical Products Administration, which aids in hemostasis and wound healing across various surgical fields[42]. - The company has received CE certification for its innovative hydrophobic injection molded aspheric intraocular lens products, with clinical trials initiated in China[62]. - The fourth-generation hyaluronic acid product has entered the clinical trial phase, indicating ongoing innovation in product development[81]. Market Opportunities - The ophthalmic market in China shows significant growth potential, with cataract surgeries estimated at 3.32 million in 2020, and a surgical implementation rate of only 2,370 per million people, compared to over 10,000 in developed countries[48]. - Over 600 million people in China are affected by myopia, with a youth myopia rate of 53.6%, indicating a growing demand for corrective products[49]. - The medical aesthetics market in China was valued at approximately 197.5 billion RMB in 2020, accounting for 17% of the global market, with expectations to become the largest market globally[49]. - The market for topical recombinant human epidermal growth factor products was about 690 million RMB in 2020, projected to grow to 1.309 billion RMB by 2026, with a CAGR of approximately 9.84%[50]. - There are over 100 million osteoarthritis patients in China, highlighting a significant treatment opportunity for joint health products[50]. Acquisitions and Partnerships - The company has completed the acquisition of a strategic partner, enhancing its product portfolio and distribution capabilities[2]. - The company holds a 55% stake in Hengtai Vision, gaining exclusive distribution rights for high-end orthokeratology lenses "myOK" and children's myopia management lenses "Beishide" in China[35]. - The company has invested in Hebei Xinshi Kang, acquiring a 60% stake to enhance its product offerings in soft contact lenses with myopia correction and cosmetic attributes[35]. Environmental and Regulatory Compliance - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission treatment systems, which are operating normally and meeting discharge standards[180]. - The company received environmental impact assessment approvals for its projects, including the expansion of epidermal growth factor production and the international pharmaceutical R&D project in November 2019[183]. - Continuous online monitoring of key pollutants in wastewater and air emissions is conducted, with data subject to supervision by environmental authorities[185]. - The company has established emergency response plans for environmental incidents, filed with the local environmental authority in December 2020[184]. Financial Management and Investments - The company reported a significant increase in investment income, which rose by 93.83% to ¥27,312,009.43 from ¥14,090,703.38 year-on-year[141]. - The total investment scale for ongoing projects amounts to ¥41,050.00 million, with a cumulative investment of ¥22,515.85 million[75]. - The company made a new equity investment of CNY 54 million during the reporting period, while the total equity investment decreased by 13.74% year-on-year[154]. - The net cash outflow from investment activities rose sharply to CNY 801,385,495.61, largely due to effective cash management and investments in time deposits and unsecured promissory notes[146]. Shareholder and Governance - The company has committed to not transferring or entrusting the management of its pre-IPO shares for 36 months from the date of listing on the Shanghai Stock Exchange[191]. - A total of 164.9 million shares are subject to a 12-month lock-up period from the date of listing, and 135.1 million shares are subject to a 36-month lock-up period[198]. - The company has established a limit on the annual transfer of shares by certain shareholders to not exceed 25% of their total holdings during their tenure as directors or senior management[196].

Financial Performance - The company's operating revenue for 2020 was approximately ¥1.33 billion, a decrease of 16.95% compared to ¥1.60 billion in 2019[12]. - The net profit attributable to shareholders for 2020 was approximately ¥230 million, down 37.95% from ¥371 million in 2019[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥206 million, a decrease of 42.25% compared to ¥357 million in 2019[12]. - The net cash flow from operating activities for 2020 was approximately ¥262 million, down 24.89% from ¥349 million in 2019[12]. - The company's total assets at the end of 2020 were approximately ¥6.30 billion, an increase of 2.39% from ¥6.15 billion at the end of 2019[12]. - The net assets attributable to shareholders at the end of 2020 were approximately ¥5.49 billion, a slight increase of 0.66% from ¥5.45 billion at the end of 2019[12]. - Basic and diluted earnings per share for 2020 were both ¥1.30, a decrease of 42.73% from ¥2.27 in 2019[13]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in the revenue share of high-margin hyaluronic acid products[59]. - The company's revenue in the pharmaceutical manufacturing industry reached 2,485.73 billion yuan in 2020, with a year-on-year growth rate of 4.5%[29]. Dividend Policy - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - The total share capital of the company as of the report date is 176,622,100 shares[2]. - The company does not plan to increase capital reserves or issue bonus shares[2]. - The company has not made any adjustments to its cash dividend policy during the reporting period[162]. - The cash dividend distribution for the 2018 fiscal year was 5.00 RMB per 10 shares, totaling 80,022,650.00 RMB, which was 19.30% of the net profit attributable to shareholders[164]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019, reflecting a rise of 2.25 percentage points[13]. - The group’s R&D expenses amounted to CNY 126.47 million, an increase of CNY 10.40 million or 8.96% compared to the previous year, with R&D expenses accounting for 9.49% of operating income, up from 7.24%[42][44]. - The company continues to invest in R&D, collaborating with universities and research institutions to advance new technologies and product development[34]. - The company has established four major technology platforms, including artificial lenses and medical chitosan, with leading industry technology levels and independent intellectual property rights[52]. - The company has a comprehensive range of products from basic foldable monofocal intraocular lenses to high-end foldable multifocal lenses, establishing itself as a leader in the domestic intraocular lens field[37]. Market Position and Product Development - The company is the largest producer of orthopedic joint cavity viscoelastic supplements in China, with a market share increase from 39.67% to 42.06% over six consecutive years[32]. - The company holds a 45.85% market share in the ophthalmic viscoelastic agent sector, maintaining this position for 13 years[31]. - The company’s recombinant human epidermal growth factor product has captured a market share of 23.49%, ranking second in the market and narrowing the gap with the leader[32]. - The company is the leading manufacturer of surgical anti-adhesion products in China, with a market share of 29.64% for 13 consecutive years[32]. - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. Operational Risks and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has ensured the accuracy and completeness of the annual report[2]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[3]. - The report includes a comprehensive discussion of operational risks and factors affecting performance[3]. - There are no non-operating fund occupations by controlling shareholders or related parties[3]. Strategic Acquisitions and Partnerships - The company acquired a 63.64% stake in Euro-Medical Technology in February 2021, expanding its medical aesthetics product line into RF and laser medical devices[21]. - The company has obtained exclusive rights to distribute Eirion's innovative botulinum toxin products in Greater China, marking its entry into the botulinum toxin and small molecule drug markets[21]. - The company initiated a strategic partnership to acquire 55% of Hengtai Vision for a total of CNY 25 million, enhancing its position in the myopia management market[67]. Compliance and Corporate Governance - The company has committed to a profit distribution policy since April 3, 2019, which is effective indefinitely[173]. - The company reported a commitment to avoid any form of fund occupation by its controlling shareholders and related parties, effective from April 3, 2019, and this commitment is long-term valid[172]. - The company will maintain compliance with the Company Law and Securities Law of the People's Republic of China in all its operations and transactions[171]. - The company has established measures to stabilize its stock price, as detailed in its prospectus under investor protection commitments[172]. Employee and Supplier Relations - The company emphasizes employee development by providing diverse training programs and has established a comprehensive training management system[195]. - The company adheres to GMP and ISO standards in supplier selection to ensure product quality and mitigate supply chain risks[198]. - The company conducts regular customer satisfaction surveys to gather feedback and improve product and service quality[200]. - The company actively engages with suppliers to maintain a fair and transparent procurement process, protecting supplier rights[198].

Financial Performance - Operating revenue for the period was ¥382,585,206.31, representing a significant increase of 149.05% year-on-year[4] - Net profit attributable to shareholders was ¥96,992,749.11, a turnaround from a loss of ¥24,855,428.82 in the same period last year[4] - Basic earnings per share for the period was ¥0.55, compared to a loss of ¥0.14 per share in the previous year[4] - The company reported a total of ¥3,984,796.31 in non-recurring gains and losses for the period[5] - The company achieved operating revenue of RMB 382.59 million, an increase of RMB 228.97 million or 149.05% compared to the same period last year[11] - The net profit attributable to shareholders was RMB 96.99 million, a turnaround from a loss of RMB 24.86 million in the same period last year[12] - Total operating revenue for Q1 2021 reached RMB 382,585,206.31, a significant increase from RMB 153,614,830.20 in Q1 2020, representing a growth of 149.5%[20] - Net profit for Q1 2021 was RMB 99,315,085.73, compared to a net loss of RMB 28,408,114.30 in Q1 2020, indicating a turnaround in profitability[20] - The company reported a basic earnings per share of RMB 0.55 for Q1 2021, compared to a loss per share of RMB -0.14 in Q1 2020[21] - Total comprehensive income for Q1 2021 was RMB 120,373,389.52, a significant recovery from a loss of RMB -80,366,877.89 in Q1 2020[21] Cash Flow - Net cash flow from operating activities was ¥15,609,445.06, a significant improvement from a negative cash flow of ¥54,461,823.95 in the same period last year[4] - Cash flow from operating activities totaled RMB 375,765,049.92 in Q1 2021, compared to RMB 270,287,164.05 in Q1 2020, showing improved cash generation[24] - In Q1 2021, the net cash flow from operating activities was -30,284,718.27, compared to -28,836,899.02 in Q1 2020, indicating a decline in operational cash flow[26] - The total cash inflow from investment activities was 68,757,274.04, up from 32,979,522.42 in the same period last year, reflecting an increase in investment returns[26] - The net cash flow from investment activities was -190,312,463.07, significantly worse than -43,738,637.18 in Q1 2020, highlighting increased investment expenditures[26] - The total cash flow for the period showed a net decrease of -222,592,297.29, compared to -72,714,182.45 in Q1 2020, reflecting overall financial strain[26] Assets and Liabilities - Total assets at the end of the reporting period reached ¥6,402,802,145.37, an increase of 1.65% compared to the end of the previous year[4] - Current assets totaled ¥3,770,803,864.17, slightly down from ¥3,809,958,571.16 at the end of 2020, indicating a decrease of about 1.02%[16] - Non-current assets increased to ¥2,631,998,281.20 from ¥2,488,746,817.00, reflecting a growth of approximately 5.73%[16] - Total liabilities decreased to ¥547,186,310.43 from ¥564,462,942.74, showing a reduction of approximately 3.06%[17] - Shareholders' equity increased to ¥5,855,615,834.94 from ¥5,734,242,445.42, representing a growth of about 2.11%[17] - The company reported an increase in accounts receivable to ¥365,695,416.59 from ¥333,527,490.76, which is an increase of approximately 9.63%[16] - Inventory levels rose slightly to ¥258,395,227.48 from ¥255,126,944.53, indicating a growth of about 0.89%[16] Research and Development - Research and development expenses accounted for 9.55% of operating revenue, a decrease of 8.91 percentage points from the previous year[4] - Research and development expenses amounted to RMB 36.53 million, representing a growth of 28.82% year-on-year[13] - Research and development expenses increased to RMB 36,527,079.45 in Q1 2021, up from RMB 28,354,664.31 in Q1 2020, reflecting a focus on innovation[20] Shareholder Information - The company had a total of 7,411 shareholders at the end of the reporting period[6] - The top shareholder, Jiang Wei, held 25.17% of the shares, totaling 44,449,000 shares[6] Other Financial Metrics - The weighted average return on equity was 1.75%, compared to -0.46% in the previous year[4] - The company reported a significant decrease in other income by 52.45% to RMB 4.75 million, attributed to reduced government subsidies compared to the previous year[11] - The company recorded investment income of RMB 13,750,368.57 in Q1 2021, a significant increase from RMB 3,351,610.11 in Q1 2020, indicating better investment performance[20] - Sales expenses rose to RMB 122,111,278.28 in Q1 2021, compared to RMB 114,868,235.77 in Q1 2020, indicating increased investment in sales efforts[20] - The company reported a total operating cost of RMB 284,719,567.04 in Q1 2021, up from RMB 193,029,975.02 in Q1 2020, reflecting higher operational expenses[20]

2020 年報 | | | | 2 | 公司資料 | | --- | --- | | 4 | 財務摘要 | | 5 | 主席致辭 | | 7 | 管理層討論與分析 | | 24 | 董事會報告 | | 46 | 企業管治報告 | | 67 | 企業社會責任 | | 69 | 董事、監事及高級管理人員簡介 | | 78 | 獨立核數師報告 | | 84 | 綜合損益及其他綜合收益表 | | 86 | 綜合財務狀況表 | | 88 | 綜合權益變動表 | | 90 | 綜合現金流量表 | | 93 | 財務報表附註 | | 185 | 釋義 | | 188 | 技術詞彙 | 公司資料 第四屆董事會 執行董事： 侯永泰博士 （主席） 吳劍英先生 （總經理） 陳奕奕女士 唐敏捷先生 （財務總監） 非執行董事： 游捷女士 黃明先生 獨立非執行董事： 李穎琦女士 姜志宏先生 蘇治先生 楊玉社先生 趙磊先生 第四屆監事會 劉遠中先生 （主席） 楊青女士 唐躍軍先生 魏長征先生 楊林鋒先生 授權代表 黃明先生 趙明璟先生 聯席公司秘書 田敏女士 趙明璟先生 （香港特許秘書公會資深會員） 審計委員會 李穎琦女士（ 主席） 游捷 ...

Financial Performance - The company's operating revenue for 2020 was approximately CNY 1.33 billion, a decrease of 16.95% compared to 2019[12]. - The net profit attributable to shareholders for 2020 was approximately CNY 230 million, down 37.95% from the previous year[12]. - The net profit after deducting non-recurring gains and losses was approximately CNY 206 million, a decrease of 42.25% compared to 2019[12]. - The basic earnings per share for 2020 was CNY 1.30, a decline of 42.73% from 2019[13]. - The company's total assets at the end of 2020 were approximately CNY 6.30 billion, an increase of 2.39% from the end of 2019[12]. - The company's net assets attributable to shareholders at the end of 2020 were approximately CNY 5.49 billion, an increase of 0.66% from the end of 2019[12]. - The company reported a quarterly revenue of CNY 440 million in Q4 2020, showing a positive trend in the latter half of the year[15]. - The company experienced a net loss of approximately CNY 25 million in Q1 2020, indicating challenges at the beginning of the year[15]. - The company achieved a total revenue of RMB 133,145.11 million in 2020, a decrease of RMB 27,087.37 million or 16.91% compared to the previous year[59]. - The overall gross margin for the company was 74.91% in 2020, down from 77.28% in 2019, primarily due to a significant decrease in revenue from high-margin hyaluronic acid products[59]. Dividend Distribution - The company plans to distribute a cash dividend of 5 RMB per 10 shares, totaling 88,311,050 RMB, which accounts for 38.38% of the net profit attributable to shareholders for 2020[2]. - In 2020, the company distributed cash dividends of 7.00 RMB per 10 shares, totaling 124,044,620.00 RMB, which accounted for 33.46% of the net profit attributable to shareholders[155]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.49% in 2020, up from 7.24% in 2019[13]. - The R&D expenses for the reporting period amounted to CNY 126.47 million, an increase of CNY 10.40 million, representing a growth rate of 8.96%[42]. - The company has increased its R&D investment to enhance new technology and product development, focusing on collaboration with universities and research institutions[34]. - The company has established a comprehensive R&D system with 270 R&D personnel, accounting for 19.65% of total employees[119]. - The company is actively collaborating with domestic and international universities and research institutions to enhance its R&D capabilities and technology transfer[123]. Market Position and Product Lines - The company has established four major product lines in ophthalmology, medical aesthetics, wound care, and orthopedics, focusing on innovative medical products[19]. - The company is a leading domestic manufacturer of ophthalmic viscoelastic devices and intraocular lenses, with a complete product portfolio covering various materials and optical designs[19]. - The company is the largest domestic producer of orthopedic joint cavity viscoelastic supplements, with a complete range of hyaluronic acid injection products[23]. - The company is the largest producer of surgical anti-adhesion agents in China, with a market share of 29.64% in 2019, maintaining the top position for 13 consecutive years[32]. - The company holds a 45.85% market share in the domestic ophthalmic viscoelastic agent market and nearly 30% in the artificial lens market[64]. Compliance and Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[2]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[2]. - The company has not violated decision-making procedures for external guarantees[3]. - There are no special arrangements for corporate governance[3]. - The company has committed to measures to compensate for any dilution of immediate returns since April 3, 2019, which is also valid for the long term[166]. Environmental Management - The company reported a total wastewater discharge of 76,092 tons and managed to keep all pollutant emissions within regulatory limits during the reporting period[198]. - The company processed 31.5259 tons of general waste and 44.6409 tons of hazardous waste, demonstrating its commitment to environmental management[198]. - The company has implemented effective waste treatment methods, ensuring compliance with environmental regulations for both wastewater and air emissions[199]. - The company has completed the construction of environmental protection facilities, including wastewater treatment and air emission terminal treatment facilities[200]. Strategic Initiatives - The company aims to enhance the quality of life for Chinese citizens and promote patient recovery, focusing on differentiated development in ophthalmology, aesthetic medicine, orthopedics, and surgery[149]. - The company is actively pursuing investment and acquisition opportunities in the global ophthalmic field to accelerate the localization of the Chinese ophthalmic industry[66]. - The company has established a strategic goal to become a leading domestic and internationally recognized biopharmaceutical enterprise in the field of biomedical materials[150]. - The company will integrate acquired businesses to maximize synergies and improve operational efficiency[151].

Financial Performance - Net profit attributable to shareholders was CNY 112,646,895.39, down 55.13% year-on-year[5] - Operating revenue for the first nine months was CNY 892,155,592.36, representing a decline of 22.06% compared to the same period last year[5] - Basic earnings per share were CNY 0.63, down 59.87% from the previous year[6] - The company reported a total revenue of RMB 892.16 million for the current period, a decrease of RMB 252.55 million or 22.06% compared to the same period last year[16] - The main business revenue was RMB 891.25 million, down RMB 251.71 million or 22.02% year-on-year[16] - The ophthalmology product line generated revenue of RMB 381.80 million, accounting for 42.84% of total revenue, a decrease of 23.88% from the previous year[16] - The orthopedic product line revenue was RMB 224.61 million, representing 25.20% of total revenue, down 11.12% year-on-year[16] - The company reported a total operating cost of ¥317,248,919.13 for Q3 2020, compared to ¥299,886,373.78 in Q3 2019, indicating an increase of approximately 5.5%[27] - The company reported a total comprehensive income of ¥21,558,659.11 for Q3 2020, compared to ¥9,375,995.01 in Q3 2019, indicating an increase of approximately 130%[30] Cash Flow and Investments - The net cash flow from operating activities was CNY 110,051,983.31, a decrease of 45.17% year-on-year[5] - The company reported a net cash outflow from investing activities of CNY -381,425,700.69, primarily due to new investment agreements[20] - The company’s total cash outflow from operating activities was 308,036,938.41 RMB, slightly lower than 310,538,577.16 RMB in the same period of 2019[33] - The company reported a significant decrease in cash received from other operating activities, totaling 12,128,171.10 RMB, down from 25,591,020.00 RMB in the same period of 2019[33] - The company experienced a net cash outflow from investment activities of -53,687,241.10 RMB, compared to a positive cash flow of 68,443,479.99 RMB in the prior year[34] - Cash and cash equivalents at the end of the period stood at 303,326,921.67 RMB, down from 46,332,226.90 RMB in the previous year[34] Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,145,082,708.57, a decrease of 0.11% compared to the end of the previous year[5] - The total liabilities increased to CNY 558,874,882.17 from CNY 498,516,864.48 at the end of 2019[23] - The company reported a decrease in accounts receivable to CNY 316,448,358.65 from CNY 381,990,938.69 year-on-year[22] - The company’s total liabilities as of September 30, 2020, were ¥320,395,320.67, compared to ¥177,729,022.12 in the previous year, showing a significant increase[26] - The total equity attributable to shareholders decreased to ¥4,152,760,978.36 from ¥4,287,888,951.10 at the end of 2019[26] Research and Development - Research and development expenses accounted for 9.43% of operating revenue, an increase of 2.49 percentage points compared to the previous year[6] - Research and development expenses for Q3 2020 were ¥27,529,488.77, slightly down from ¥28,105,188.21 in Q3 2019[27] - Research and development expenses for Q3 2020 were ¥8,615,954.67, a decrease from ¥11,799,584.47 in Q3 2019, representing a reduction of about 27%[29] Market and Product Development - The company anticipates a recovery in domestic business, with major product lines showing positive growth trends in the third quarter[17] - The company plans to continue expanding its product offerings and market presence through strategic initiatives and product differentiation[18] - The launch of the third-generation hyaluronic acid product "Hai Mei" occurred on August 7, 2020, aimed at consolidating the company's leadership in the domestic hyaluronic acid market[18] - The company successfully participated in bulk procurement for high-value medical consumables in various provinces, enhancing market share for its intraocular lens products[18] Shareholder Information - The total number of shareholders at the end of the reporting period was 5,567[8]